VOYAGER THERAPEUTICS INCVYGR
ASignal's systematic analysis rates VYGR as Bearish.
Reflects the latest available analysis · analyzed Oct 18, 2026
The case on VYGR
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong financial health score (0.9)
- High current ratio (7.50x) indicating solid short-term liquidity
- Low debt-to-equity ratio (0.21x) suggesting limited leverage risk
- Cash-rich balance sheet with $116.34M cash vs $32.57M debt
- RSI at 16.1, indicating deeply oversold conditions
- Severely negative operating margin (-833.87%)
- Negative gross margin (-236.81%) indicating core business unprofitability
- Negative return on equity (-54.09%) and return on assets (-27.34%)
- Negative free cash flow (-$77.31M) and operating cash flow (-$120.57M)
- Revenue growth declining YoY by 39.1%
- EV/EBITDA of -0.30x reflects unprofitability
See the full verdict on VYGR
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes VYGR
Most investors never get a second opinion, let alone several. ASignal runs VYGR past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.